WHATEVER YOU CAN DO, or dream you can, begin it. Boldness has genius, power and magic in it.

- JOHANN WOLFGANG VON GOETHE

SYNGAP RESEARCH FUND

Collaboration. Transparency. Urgency.

Mike - Tony's Dad & SRF's Founder

Left my career a few years ago to lead SRF. In addition to working with the team of SynGAP families and partners, I serve on Executive Board of COMBINEDBrain, AES Epilepsy Research Benchmarks Stewards Committee and work closely with Innovation and Value Initiative Methods Summit &



Professional background in global development, healthcare strategy, finance

and planning at top-tier institutions



Educational background in Mathematics (BS), International Economics (MA) and Finance (MBA).







SynGAP Research Fund dba @cureSYNGAP1

SynGAP Research Fund - a family-led, volunteer-driven 501 (c)(3) public charity

To improve the lives of patients and families suffering from SynGAP1- RD Mission

An expeditious development of SynGAP1-RD treatments and cures Vision accelerated by funding of high impact research, partnering with passionate industry leaders and supporting our driven and mobilized DEE community.

Mantra Strategic Areas

Volunteer Teams

Provide Education and Support to the SynGAP1 Community

Community Activation Advocacy SRF Patient Conference

Collaboration, Transparency & Urgency

Expand Scientific Awareness & Stakeholders of SynGAP1-RD

Effective Partnerships

SRF Scientific Conference

Support and Initiate Scientific Research to Advance SynGAP1-RD Treatments and Cures

Medical/Science Initiatives Communications and Marketing Resource Management Fundraising

Overview: SRF in numbers

Provide Education and Support to the SynGAP1 Community												
1,581	240	210	23	5								
Patients Counted	Patients in citizen health	Patients profiled	Families were/are Trustees	Geographies								
Expa	nd Awareness of SynGAP1	-RD	Support and Initiate So	cientific Research								
100+	3	1	~30	\$6.25M								
Webinar available	Podcasts in 2 languages	ICD-10	Institutions supported	Committed to grants								

Advancing *SYNGAP1* Science: SRF's Seven Core Scientific Programs

Our comprehensive programs focus on understanding the disease, accelerating research, and preparing for clinical trials.

Our commitment to funding strategic initiatives reflects our urgency to drive breakthroughs and find treatments.


BTS	PUR ^P SE	SMART	SBOM	FACILITATE	SRDC	SYNGAP1 Pr • MMiS
Basic and Translational	Drug Repurposing	SYNGAP1 Missense Analysis,	SYNGAP1 Biomarkers and	Research Tools and Reagents	SYNGAP1-Related Disorders	Natural History Study at
Science		Research, and Therapeutics	Endpoints		Characterization	Multidisciplinary Clinics
Basic science reveals what	Drug repurposing looks to	Studying missense variants	Biomarkers (e.g. in blood,	Creating and indexing	A long-term, rich	A highly curated prospective
goes wrong in tissues and	reduce suffering in patients in	can help identify effective	CSF, EEGs, actigraphy) and	research tools and reagents	characterization of SRD is	study, executed across
cells when a SYNGAP1 gene	the short term.	treatments for individual	clinical measures (ORCA,	helps SYNGAP1 research	essential for successful clinical	multiple multidisciplinary
is broken. Translational	SRF's process of Find,	missense variants, discover	Bayley, etc.) are required to	partners. We have	trials and for improved clinical	clinics, is needed to describe
science is the designing and	Assess, Survey, and Trial	more druggable targets for all,	determine treatment efficacy	biorepository samples, iPSC	care of our patients.	"standard of care" when
testing of different types of	existing medicines for use in	and provide a more nuanced	and disease progression, and	lines, curated data, and more.		testing new treatments. Also
medicines for SRD.	SRD may improve care and	view of SRD.	may improve diagnostics.			builds future trial sites.
	reduce medication burden.					
SRF Funding to Date:	SRF Funding to Date:	SRF Funding to Date:	SRF Funding to Date:	SRF Funding to Date:	SRF Funding to Date:	SRF Funding to Date:
\$1,716,545	\$1,654,901	\$610,160	\$562,250	\$795,283	\$449,513	\$454,115

*\$ as of December 31, 2024

SRF Scientific Funding to Date: \$6,242,768

cureSYNGAP1.org/Grants






1998

202<u>5:18</u>

SRD THERAPEUTIC PIPELINE | March 2025



First five years

It gets complicated fast - I have ~20 grants in flight today.


Year	Institution	Prof/Focus	Commitment	= Remaining +	Year	Institution	Prof/Focus	Commitment	= Remaining +
2018	Hopkins	Huganir	\$500,000	Fully Funded	2022	Rarebase	FM 38, 40, 41, 45	\$570,000	\$213,750
2018	Scripps	Rumbaugh	\$205,500	Fully Funded	2022	Hopkins	Coller	\$130,000	\$65,000
2018	Baylor	Holder	\$130,000	Fully Funded	2022	Edinburgh	Cobb/Kind	\$183,545	\$183,545
2019	UCSF	Lowenstein	\$10,000	Fully Funded	2022	USC	Quadrato	\$130,000	\$41,043
2019	Penn	Heller	\$130,000	Fully Funded	2022	Harvard/BCH/Axo	r Xin/Kadam	\$140,000	Fully Funded
2020	Ciitizen	Brimble	\$40,000	Fully Funded	2023	Cornell	Cunnane (Med Stu)	\$5,000	Fully Funded
2020	USC	Coba / Quadrato	\$46,500	Fully Funded	2023	Utah	Chow	\$65,377	Fully Funded
2020	JCU	Frazier	\$14,200	Fully Funded	2024	AES/CHOP	McKee	\$10,000	Fully Funded
			Section Street Provide M		2023	Stanford	Knowles	\$130,000	\$65,000
2020	USC	Coba	\$130,000	Fully Funded	2023	JCU	Frazier	\$105,000	\$13,609
2021	Harvard	DSC	\$70,191	Fully Funded	2023	Turku	Postilla	\$100,000	\$50,000
2021	Harvard	Poduri	\$238,133	\$65,133	2023	Toronto	Andrade	\$156,380	\$78,190
2021	Rarebase	IPSC	\$63,750	Fully Funded	2023	Ottawa	Lacoste	\$25,000	\$15,000
2021	Combined Brain	IPSC	\$1,286	Fully Funded	2023	Cornell	Grinspan	\$100,000	\$100,000
2021	Rarebase	Function, round 1	\$150,000	Fully Funded	2023	NYU	Devinsky	\$50,000	\$50,000
2022	Canada Models	UBC & Montreal	\$19,672	Fully Funded	2023	Florey	Waters	\$7,000	\$7,000
2022	Nebraska	Zempleni	\$99,909	Fully Funded	2023	Jax	Simon	\$186,700	\$186,700
2022	Probably Genetic	Lukas Lange	\$15,600	Fully Funded	2023	Nebraska	Zempleni	\$196,672	\$196,672
2022	UC Davis	Joe Anderson	\$148,000	\$20,000	2024	UCSF	Willsey	\$130,000	\$130,000
2022	Fundacion NICE	Aledo	\$1,250	Fully Funded	2024	U. Ottawa	Lacoste	\$128,888	\$128,888
2022	Penn	MDBR	\$65,000	Fully Funded	2024	Edinburgh (UK)	Donlin-Asp	\$130,000	\$130,000
2022	Jackson Labs	TBD	\$42,700	\$15,647	2024			to contract on the restore	Concercit a property
2022	Turku	Courtney	\$187,299	\$0	2024	Jax	Simon	\$186,700	\$186,700
2022	McGill	Bowie	\$115,000	\$58,388				\$5,290,252	\$2,000,265

Build community and leverage giving: 1:2:6

		2018	2019	2020	2021	2022	Total	Notes
990 Revenue (line 12)	A	\$20,000	\$382,888	\$590,087	\$1,357,074	\$2,144,228	\$4,494,277	
990 Expense (line 18)	В	0	\$52,910	\$225,407	\$874,679	\$1,192,705	\$2,345,701	
Net	A - B	\$20,000	\$329,978	\$364,680	\$482,395	\$951,523	\$2,148,576	;
Direct Payments	F = C+D+E	\$361,833	\$0	\$0	\$250,000	\$0	\$611,833	Donors direc
Total SRF Raised	G = A+F	\$381,833	\$382,888	\$590,087	\$1,607,074	\$2,144,228	\$5,106,110)
Total SRF Spent	H = B+F	\$361,833	\$52,910	\$225,407	\$1,124,679	\$1,124,679 \$1,192,705		
Spend	H/G	94.8%	13.8%	38.2%	70.0%	55.6%	57.9%	,
Founders Gifts to SRF	1	\$20,000	\$51,701	\$51,758	\$209,317	\$175,000	\$507,776	;
Founders Gifts via other	J	0	\$0	\$0	\$0	\$0	C	Need to find
Founders Direct giving	С	\$111,833	\$0	\$0	\$0	\$0	\$111,833	5
Total Founder Spend	K = I + J + C	\$131,833	\$51,701	\$51,758	\$209,317	\$175,000	\$619,610	62
% SRF Revenue	K/G	34.53%	13.50%	8.77%	13.02%	8.16%	12.13%	5
Founders Soft Credits	L	0	\$255,000	\$84,500	\$51,079	\$233,006	\$623,585	conservative
Founder Direct Donors	M = D+E	\$250,000	0	0	\$250,000	195000	\$695,000	
Total Founder Impact	N = K + L + M	\$381,833	\$306,701	\$136,258	\$510,396	\$603,006	\$1,938,195	;
% SRF Revenue	N/G	100.00%	80.10%	23.09%	31.76%	28.12%	37.96%	5


A guarantee fund can allow you to move faster

We can't raise funds till we have a project and we can't start a project till we have funds...



Approve Work

Say yet to good work and get it going... grant agreements and hiring.



Raise against the project

With a motivated scientist and concrete project people will join you

Best stuff I did was cheap and now it's cheaper

Join COMBINEDbrain/Biobank

(BTW - People raise way more money for their own mutation/etc.)

iPSCs - CAMP4 Story

Census - Start now.

Podcast - Just do it, you can always delete it if it's terrible.

SynGAP Research Fund (SRF) for SYNGAP1-Related Diso... SRF 3.981 followers 43m • 🕥 How many people have SYNGAP1? 1025 #SYNGAPcensus = @ 1.581 Details: https://lnkd.in/g79jZmPe **449** = 129 # 128 **114** 1113 **=** 55 53 52 **# 47 4**5 ▶ 42 **3**4 **3**3 :: 22 20 15 13 12 11 L 10 9 • 1 8 **m** 7 +==6 5 2

If we missed you, let us know! #SYNGAP1 #SYNGAPCensus #CureSYNGAP1

SRF has three SYNGAP1 podcasts for patient finding & support



Episodes V

SATURDAY · VIDEO

113. Fondo sets the bar for LatAm Engage 2nd Soiree was a hit, grants are rolling in! Super Heroine: Vicky Arteaga Fondo Syngap is tirele https://www.syngapresearchfund.org/professionals/20

SynGAP10 weekly 10 minute updates on SYN

Syngap Research Fund, 501(c)(3) ★ 5 (70) · NON-PROFIT · UPDATED WEEKLY



Mike Graglia, SRF Managing Dir, & SYNGAF difficult. Tony's experience shows that it's Show Notes Going back to school is difficult for most and other rare diseases, it is especially hard! Mike Grag

SYNGAP1 Stories Syngap Research Fund, 501(c)(3) PARENTING · UPDATED BIWEEKLY





Episodes V



Episodes V

AUGUST 29

AUGUST 20

Episodio 01: Valeria Torcetta y su hija Charo- La Primera Paciente Diagnosticada con SvnGAP1 en America Latina

Episodio #01 Bienvenidos a nuestro nuevo podcast, Café SynGAP1! En nuestro primer episodio, nos acompaña Valeria Torcetta, una invitada especial quien nos habla sobre Charo, su hija con Syngap1, y primera pa...



Café SYNGAP1

Syngap Research Fund, 501(c)(3)

PARENTING · UPDATED BIWEEKLY

Bienvenidos al nuevo podcast de SRF en Español: Café Syngap1 pretender ser un espacio para encontrar apoyo, consejos y esperanza en una comunidad de Padres, Hermanos, Investigadores, Científicos, Terapeuta: MORE

Latest Episode

What I think is important after working on this for 5+ years

Three Essential Concepts - These are ideas that you have to embrace if you are seriously going to do some fundraising


Four Major Learnings - Realizations I've had along the way and want you to know.

Ten helpful tips - These are things I've learned, generally by doing the opposite first. I have iterated relentlessly and made so many mistakes.


SynGAP R	esearch Fun	d Incorpora	ated	83-1200789	9 Page 2						
Part II Support Schedule for Organizations Described in Sections 170(b)(1)(A)(iv) and 170(b)(1)(A)(vi)											
(Complete only if you checked the box on line 5, 7, or 8 of Part I or if the organization failed to qualify under Part III. If the organization fails to qualify under the tests listed below, please complete Part III.)											
Section A. Public Support											
(a) 2018	(b) 2019	(c) 2020	(d) 2021	(e) 2022	(f) Total						
20,000.	382,888.	590,087.	1,364,391.	2,144,228.	4,501,594.						
,	(a) 2018	Comparizations Described in ad the box on line 5, 7, or 8 of Part I or y under the tests listed below, please (a) 2018 (b) 2019	Organizations Described in Sections 170(ed the box on line 5, 7, or 8 of Part I or if the organization y under the tests listed below, please complete Part II (a) 2018 (b) 2019 (c) 2020	ed the box on line 5, 7, or 8 of Part I or if the organization failed to qualify un y under the tests listed below, please complete Part III.) (a) 2018 (b) 2019 (c) 2020 (d) 2021	r Organizations Described in Sections 170(b)(1)(A)(iv) and 170(b)(1)(A) ed the box on line 5, 7, or 8 of Part I or if the organization failed to qualify under Part III. If the y under the tests listed below, please complete Part III.) (a) 2018 (b) 2019 (c) 2020 (d) 2021 (e) 2022						

Disclaimer: The Sky is Falling (as it did with COVID) but you can lay lots of groundwork now.

Markets down...



Yields up...




World unpegging from USD...



You are exactly where you need to be.

Don't waste time doubting yourself, your loved ones can't afford it.

Jump in and own what you are doing, it's incredibly hard and important. You can't afford self-sabotage.



The universe is naturally abundant

You have to have this mindset if you are fundraising.

Do not talk yourself out of believing you will find the money.

If you don't believe it, who will?




Our capital is rare - Seed, Risk tolerant & Catalytic

What do you say when they ask "Why should I give you money?"

Our deep commitment to disease X means we will take risks nobody else will, this isn't an opportunity, it's an obligation.

It can be catalytic to other capital — otherwise we are kidding ourselves — we are also scaffolding or de-risking the target.

- 1. Getting researchers data for larger grants and seeing out assets in their labs.
- 2. Scaffolding the target Developing assets like iPSCs or models.
- 3. De-risking the target Developing clinical trial endpoints, natural history, etc.



e.g. Your work increases your scores on tables like this.

																	
	US / EU	Target	Gene				Тx	Nat	PC	Clin.	Pat.				Clin.		
Disease Name	Prevalence	Gene	Size	Inher.		Onset	Mech.	Hist.	Mod.	Dev.	Org.	SZ	ID	MD	Need	Opp.	Disease Summary
Internal Development Candidates - Genetic Neurodevelopmental Disorders & Epileptic Syndromes																	
SCN2A-Related Disorders	62,133	SCN2A	6,018	AD		<12 m	4	5	4	4	5	4	5	3	5	5	Moderate-severe ID, autism; refractory epilepsy
SCN8A-Related Disorders	57,275	SCN8A	5,943	AD		<6 m	3	5	4	3	4	3	5	4	4	5	Severe ID, refractory epilepsy with regression
Dravet Syndrome	56,031	SCN1A	5,997	AD		<12 m	5	5	5	5	5	5	5	4	5	3	Severe-profound ID, DD & intractable epilepsy
CHD2 Encephalopathy	53,183	CHD2	5,487	AD		<2 y	5	5	4	4	1	5	4	2	4	5	Moderate-severe ID with refractory epilepsy
Phelan-McDermid Syndrome	51,321	SHANK3	5,193	AD		<2 y	5	5	4	4	5	4	5	4	5	5	Moderate-severe ID, DD autism; seizures in 40%
SYNGAP1 Encephalopathy	47,491	SYNGAP1	4,032	AD		<2 y	5	5	5	5	5	5	5	4	5	5	Severe ID with up to ~200 seizures per day
GRIN2B-Related Disorder	45,960	GRIN2B	4,455	AD		<4 y	4	4	1	3	5	4	5	4	4	4	Moderate-severe ID; 50% epilepsy, >25% autism
1A Neurological Disorder	40,559	KIF1A	5,073	AD		<2 y	4	4	3	4	5	3	4	4	5	5	Severe ID, epilepsy; regression
Rett Syndrome	38,879	MECP2	1,461	XL		<18 m	4	5	5	4	5	4	5	5	5	4	Neurodegeneration with ID, autism & early death
Smith-Magenis Syndrome	31,103	RAI1	5,721	AD		<6 m	5	4	5	4	5	2	5	3	4	5	Moderate ID, DD with autism; no epilepsy
DNM1 Encephalopathy	29,408	DNM1	2,595	AD		~6 m	4	5	5	5	5	5	5	5	5	5	Profound ID, DD with intractable epilepsy
STXBP1 Encephalopathy	28,108	STXBP1	1,785	AD		<6 m	5	5	4	5	5	5	5	4	5	5	Profound ID, DD with resistant epilepsy & autism
KCNQ2 Encephalopathy	25,487	KCNQ2	2,619	AD		<1 m	4	4	4	4	5	5	5	5	5	5	Severe ID, DD and neonatal onset epilepsy
SLC8A 1-Related Disorder	20,603	SLC8A1	1,800	AD		<4 y	5	4	2	4	5	4	4	3	4	5	Moderate ID, epilepsy with regression
CDKL5 Deficiency Disorder	16,868	CDKL5	2,883	XL		<3 m	4	5	4	5	5	5	5	5	5	3	Devastating DD, ID & epilepsy
GABRB3 Associated Epilepsy	16,633	GABRB3	5,783	AD	[<12 m	4	5	4	4	3	4	4	3	4	5	Moderate ID, resistant epilepsy; ~25% autism
SETD5 Syndrome	12,388	SETD5	4,329	AD		<2 y	5	4	5	3	2	1	4	2	4	5	Moderate ID & DD; ~25% autism
PRRT2 Dyskinesia & Epilepsy	11,664	PRRT2	1,023	AD		<1 y	4	4	4	3	1	4	3	4	3	4	Infantile epilepsy, dyskinesia; some ID
CACNA1A-Related Disorders	7,776	CACNA1A	7,527	AD	[<10 y	4	3	3	4	5	4	2	4	3	4	Highly variable spectrum
GLUT1 Deficiency Syndrome	7,422	SLC2A1	1,479	AD		<1 y	5	5	5	4	5	5	4	5	4	4	Moderate ID, DD, epilepsy & motor disorder

Language & culture matters: "We can fill an unmet need together" vs "I need to raise \$100k".

The sooner you go to the community with a project and urge them to support it, the sooner this gets real.

In addition to fundraising you are activating a community.




How you fundraise will change as you grow,



It's darkest before the dawn

A stalled fundraiser feels like a public failure, it's not.

These gaps are when people who can fill gaps step forward.






PALO ALTO, Calif. Nov. 19, 2020 / PKNewswirg/ ~ The SynCAP Research Fund (SKP) announces a new research grant award to the Heller Laboratory of Neuroepigenetics in the Perelman School of Medicine at the University of Pennsylvania. The lab will receive \$130,000 over two years towards funding a postdoctoral fellow who will focus on epigenetic regulation of SynCAPI.

Donors don't love overhead, be ready to discuss.

Option 1: Good news we don't spend much on overhead!

You are just starting and working on a shoestring, so go ahead and own that.

Put a time limit on it.



Option 2: Refocus the conversation on capacity building.

We need a dedicated organization for this disease and organizations need funding to grow.

Help with your Ws: Wealth, Wisdom or Work.



10 Tips

- 1. Hire someone, this is a ton of work Virtual assistant or parent.
- 2. Plumbing matters, don't ignore it Scalable tech to move & track money.
- 3. Communicate relentlessly Podcast/Videos, Social, Newsletter.
- 4. Call people to thank and to ask You learn what matters in calls.
- 5. Throw and annual event ASAP Events trigger donations, get it going.
- 6. Don't pay overheads to large institutions They get it, put policy on your site.
- 7. Press Releases matter, use them. Eureka Alerts is reasonable.
- 8. Newly diagnosed families panic, give them something to do. Page for kiddo.
- 9. Don't skip the audit These are useful, credibility building and not that bad.
- 10. Liquidate stocks upon receipt You are not in the stock business.